AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34110033 — intervention group
Group type: EXPERIMENTAL
Intervention: D'Amico low risk
Number of subjects: 21646
Study 34110033 — intervention group
Group type: EXPERIMENTAL
Intervention: D'Amico intermediate risk
Number of subjects: 21646
Study 34110033 — intervention group
Group type: EXPERIMENTAL
Intervention: D'Amico high risk
Number of subjects: 21646
Study 34110033 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason Grade Group I (GGG I)
Number of subjects: 21646
Study 34110033 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason Grade Group II (GGG II)
Number of subjects: 21646
Study 34110033 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason Grade Group III to V (GGG III-V)
Number of subjects: 21646
Study 34110033 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥cT2
Number of subjects: 21646
Study 34110383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg/d for 3 cycles) followed by combination with venetoclax (ramp-up to 400 mg/d for 24 cycles)
Number of subjects: 80
Study 34110383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus venetoclax
Number of subjects: 80
Study 34110489 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for progressive well-differentiated NETs
Number of subjects: 47
Study 34110489 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ≥ 5 bone metastases
Number of subjects: 47
Study 34110489 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-gastroenteropancreatic (non-GEP) NETs
Number of subjects: 47
Study 34110489 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of interim ascites
Number of subjects: 47
Study 34110489 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromogranin A of ≥ 4 × upper limit of normal (ULN)
Number of subjects: 47
Study 34110489 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing ascites
Number of subjects: 47
Study 34110489 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver metastases involving greater than 50% liver volume
Number of subjects: 47
Study 34110489 — intervention group
Group type: EXPERIMENTAL
Intervention: Existence of unusual metastatic locations
Number of subjects: 47
Study 34110505 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 34110505 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 34110505 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study 34110505 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab
Number of subjects: 0
Study 34110505 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 0
Study 34110605 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 150/300 mg
Number of subjects: 2401
Study 34110605 — intervention group
Group type: EXPERIMENTAL
Intervention: etanercept
Number of subjects: 2401
Study 34110605 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2401
Study 34111495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral blood flow (CBF) and functional connectivity strength (FCS) measurements
Number of subjects: 0
Study 34111887 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence lifetime imaging ophthalmoscope (Heidelberg Engineering)
Number of subjects: 5
Study 34111887 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging artifacts (too short image acquisition time, insufficient illumination, ocular surface problems, image defocus)
Number of subjects: 5
Study 34111887 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior use of systemic or topical fluorescein
Number of subjects: 5
Study 34112151 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership support and organizational structure
Number of subjects: 23
Study 34112151 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual factors
Number of subjects: 23
Study 34112151 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership involvement
Number of subjects: 23
Study 34112154 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led empowering education using teach-back method
Number of subjects: 80
Study 34112154 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study 34112181 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific carbohydrate diet
Number of subjects: 22
Study 34112230 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for acute TAAD
Number of subjects: 0
Study 34112454 — intervention group
Group type: EXPERIMENTAL
Intervention: PREDICT-TAVR score (6-item score including blood hemoglobin, serum iron concentrations, oral anticoagulation, dual antiplatelet therapy, common femoral artery diameter, and creatinine clearance)
Number of subjects: 5185
Study 34112454 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of PREDICT-TAVR score
Number of subjects: 5185
Study 34112454 — intervention group
Group type: EXPERIMENTAL
Intervention: PREDICT-TAVR score quartiles
Number of subjects: 5185
Study 34112625 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MRI (DW-MRI)
Number of subjects: 10
Study 34112625 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT
Number of subjects: 10
Study 34112625 — intervention group
Group type: EXPERIMENTAL
Intervention: SUV-max, SUL-peak, SUV-mean
Number of subjects: 10
Study 34112707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 150 mg twice daily for 12 months
Number of subjects: 43
Study 34112707 — intervention group
Group type: COMPARATOR
Intervention: Observation group (nonrandomized control)
Number of subjects: 43
Study 34112729 — intervention group
Group type: EXPERIMENTAL
Intervention: Raghu scale for pulmonary fibrosis (R-Scale-PF)
Number of subjects: 100
Study 34112729 — intervention group
Group type: COMPARATOR
Intervention: King's Brief Interstitial Lung Disease questionnaire (K-BILD)
Number of subjects: 100
Study 34112729 — intervention group
Group type: COMPARATOR
Intervention: EuroQol Five-Dimensional Five-Level questionnaire (EQ-5D-5L)
Number of subjects: 100
Study 34112873 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis doffing
Number of subjects: 24
Study 34112873 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 24
Study 34112873 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing time
Number of subjects: 24
Study 34112948 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA kinetics based on >0.05 threshold
Number of subjects: 192
Study 34112948 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA, ctDNA, and CA19-9
Number of subjects: 192
Study 34112948 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating scoring system (CSS) combining CEA kinetics, baseline CA19-9, and cfDNA
Number of subjects: 192
Study 34113254 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingre Huoxue treatment (QRHXD/QRHXEP)
Number of subjects: 468
Study 34113254 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate plus hydroxychloroquine
Number of subjects: 468
Study 34113254 — intervention group
Group type: EXPERIMENTAL
Intervention: Both QRHXD/QRHXEP and Methotrexate plus hydroxychloroquine
Number of subjects: 468
Study 34113318 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH treatment
Number of subjects: 2792
Study 34113381 — intervention group
Group type: EXPERIMENTAL
Intervention: Readymade plastic stent with apically repositioned flap
Number of subjects: 20
Study 34113381 — intervention group
Group type: COMPARATOR
Intervention: Conventional apically repositioned flap with papillary sparing incisions
Number of subjects: 20
Study 34113569 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispecific CD19/22 CAR T cells
Number of subjects: 32
Study 34113571 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterally extended endopelvic resection (LEER)
Number of subjects: 59
Study 34113571 — intervention group
Group type: COMPARATOR
Intervention: Chemo or targeted therapy alone
Number of subjects: 59
Study 34113981 — intervention group
Group type: EXPERIMENTAL
Intervention: Total vitamin D intake (highest quartile, median: 1439 IU/d)
Number of subjects: 263
Study 34113981 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental vitamin D intake (800-1000 IU/d)
Number of subjects: 263
Study 34113981 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental vitamin D intake (>1000 IU/d)
Number of subjects: 263
Study 34113981 — intervention group
Group type: COMPARATOR
Intervention: Dietary vitamin D
Number of subjects: 263
Study 34114913 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 24
Study 34114954 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health intervention (tailored Family Gene Toolkit)
Number of subjects: 104
Study 34114954 — intervention group
Group type: COMPARATOR
Intervention: Comparison website (control)
Number of subjects: 104
Study 34115014 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral endoscopic myotomy (POEM)
Number of subjects: 20
Study 34115136 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy for SCD with nonmyeloablative conditioning and related haploidentical donors
Number of subjects: 0
Study 34115136 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy for SCD
Number of subjects: 0
Study 34115136 — intervention group
Group type: COMPARATOR
Intervention: Busulfan treatment
Number of subjects: 0
Study 34115136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing NIH-sponsored trials
Number of subjects: 0
Study 34115385 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib (40 mg)
Number of subjects: 0
Study 34115419 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcome Measure of Ataxia (70-item, scored on a 0-4 Likert scale)
Number of subjects: 147
Study 34115419 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcome Measure of Ataxia
Number of subjects: 147
Study 34115607 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensors and smartphone apps (Fitbit, Social Rhythms, Roadmap 2.0) for monitoring health and well-being
Number of subjects: 2158
Study 34115607 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveys administered through the Roadmap 2.0 app
Number of subjects: 2158
Study 34115607 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensor data and biospecimen collection
Number of subjects: 2158
Study 34115650 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir/lamivudine (DTG/3TC)
Number of subjects: 131
Study 34115805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle-trait hemoglobin
Number of subjects: 0
Study 34115946 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic variability (GV)
Number of subjects: 0
Study 34116051 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow eaters consuming rice cake meal
Number of subjects: 39
Study 34116051 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow eaters consuming white rice meal
Number of subjects: 39
Study 34116051 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow eaters
Number of subjects: 39
Study 34116051 — intervention group
Group type: COMPARATOR
Intervention: Fast eaters
Number of subjects: 39
Study 34116051 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study 34116134 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D whole-brain stack-of-spirals FISP MRF sequence at 0.55 T
Number of subjects: 19
Study 34116134 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement precision calculated from 100 simulated pseudo-replicas of in vivo data
Number of subjects: 19
Study 34116134 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-session measurement repeatability evaluation
Number of subjects: 19
Study 34116329 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS (Inhaled Corticosteroids)
Number of subjects: 846
Study 34116329 — intervention group
Group type: EXPERIMENTAL
Intervention: LABA + ICS (Long-Acting Beta-Agonists + Inhaled Corticosteroids)
Number of subjects: 846
Study 34116329 — intervention group
Group type: EXPERIMENTAL
Intervention: LABA + LAMA (Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists)
Number of subjects: 846
Study 34116329 — intervention group
Group type: EXPERIMENTAL
Intervention: LABA + LAMA + ICS (Triple therapy)
Number of subjects: 846
Study 34116329 — intervention group
Group type: COMPARATOR
Intervention: No medication (never used ICS, LABA + ICS, LABA + LAMA, or triple therapy)
Number of subjects: 846
Study 34116533 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine or 5-fluorouracil in combination with oxaliplatin or irinotecan
Number of subjects: 68
Study 34116642 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared thermography (IT) measuring skin temperature difference (Td) after thoracic paravertebral block (TPVB)
Number of subjects: 61
Study 34116642 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared thermography (IT) measuring skin temperature difference (Td)
Number of subjects: 61
Study 34116642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinprick test
Number of subjects: 61
Study 34116645 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anti-diabetic therapies
Number of subjects: 552
Study 34116645 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-hypertensive therapies
Number of subjects: 552
Study 34116645 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapies
Number of subjects: 552
Study 34116645 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapies
Number of subjects: 552
Study 34116645 — intervention group
Group type: COMPARATOR
Intervention: HbA1c treatment target not achieved (HbA1c ≥ 7.0%)
Number of subjects: 552
Study 34116645 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure treatment target not achieved (BP ≥ 140/90 mmHg)
Number of subjects: 552
Study 34116645 — intervention group
Group type: COMPARATOR
Intervention: LDL-cholesterol treatment target not achieved (LDL-cholesterol ≥ 2.6 mmol/L)
Number of subjects: 552
Study 34116675 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diets (LED)
Number of subjects: 71
Study 34116699 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of depression services into NCD care
Number of subjects: 19
Study 34116699 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of antidepressants at the clinic
Number of subjects: 19
Study 34116699 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of NCD staff on depression assessment and care
Number of subjects: 19
Study 34116699 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging hospital leaders to create an integration policy
Number of subjects: 19
Study 34116699 — intervention group
Group type: EXPERIMENTAL
Intervention: Reorganizing clinic flow
Number of subjects: 19
Study 34116699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing trainings and supervisions
Number of subjects: 19
Study 34116727 — intervention group
Group type: EXPERIMENTAL
Intervention: ABLE intervention (8-week home-based occupational therapy program)
Number of subjects: 20
Study 34116727 — intervention group
Group type: EXPERIMENTAL
Intervention: ABLE intervention
Number of subjects: 20
Study 34116727 — intervention group
Group type: COMPARATOR
Intervention: Usual occupational therapy
Number of subjects: 20
Study 34116727 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment and retention
Number of subjects: 20
Study 34116953 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic resorbable parietal mesh (P4HB)
Number of subjects: 94
Study 34116953 — intervention group
Group type: COMPARATOR
Intervention: Biologic mesh
Number of subjects: 94
Study 34116953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 94
Study 34117049 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular assessment, motor assessment, neurocognitive tests, cognitive-motor interaction assessment
Number of subjects: 225
Study 34117049 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular dysfunction assessment
Number of subjects: 225
Study 34117077 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid Receptor Antagonists
Number of subjects: 0
Study 34117077 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34117380 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 μg/day fluocinolone acetonide implant (FAi)
Number of subjects: 87
Study 34117510 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-induced hyperglycemic (SIH) group
Number of subjects: 250
Study 34117510 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia group (including SIH and DH)
Number of subjects: 250
Study 34117510 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial blood glucose level
Number of subjects: 250
Study 34117510 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia group
Number of subjects: 250
Study 34117510 — intervention group
Group type: EXPERIMENTAL
Intervention: On-admission hyperglycemia
Number of subjects: 250
Study 34117601 — intervention group
Group type: EXPERIMENTAL
Intervention: Home spirometry for IPF
Number of subjects: 178
Study 34117601 — intervention group
Group type: EXPERIMENTAL
Intervention: Site spirometry for IPF
Number of subjects: 178
Study 34117601 — intervention group
Group type: EXPERIMENTAL
Intervention: Home spirometry for non-IPF ILD
Number of subjects: 178
Study 34117601 — intervention group
Group type: EXPERIMENTAL
Intervention: Site spirometry for non-IPF ILD
Number of subjects: 178
Study 34117601 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical functional capacity measured by daily home accelerometry for IPF
Number of subjects: 178
Study 34117601 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk distance (6MWD) for IPF
Number of subjects: 178
Study 34117601 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk distance (6MWD) for non-IPF ILD
Number of subjects: 178
Study 34117601 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs) for IPF and non-IPF ILD
Number of subjects: 178
Study 34117626 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 2214
Study 34117626 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 2214
Study 34117626 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 2214
Study 34117626 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 2214
Study 34117626 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 2214
Study 34117638 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TTE) strain analysis
Number of subjects: 70
Study 34117737 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. methylprednisolone (500 mg for 3 consecutive days, total of 1500 mg) followed by i.v. Tocilizumab (8 mg/kg) on day 3 and thereafter weekly s.c. Tocilizumab injections (162 mg) over 52 weeks
Number of subjects: 18
Study 34117737 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab monotherapy
Number of subjects: 18
Study 34117737 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid pulse therapy
Number of subjects: 18
Study 34117759 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased X- and Y-chromosome dosage
Number of subjects: 306
Study 34117759 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of X- and Y-chromosome-linked WMV changes
Number of subjects: 306
Study 34117759 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD-driven WMV changes
Number of subjects: 306
Study 34118018 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 2% testosterone gel 300 mcg/day (T group)
Number of subjects: 81
Study 34118018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (T + E group)
Number of subjects: 81
Study 34118018 — intervention group
Group type: COMPARATOR
Intervention: Local non-hormonal moisturizers (NH group)
Number of subjects: 81
Study 34118018 — intervention group
Group type: COMPARATOR
Intervention: Local estrogens (E group)
Number of subjects: 81
Study 34118197 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralsetinib 400 mg once-daily oral treatment
Number of subjects: 233
Study 34118198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralsetinib 400 mg once-daily oral treatment
Number of subjects: 142
Study 34118198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralsetinib
Number of subjects: 142
Study 34118361 — intervention group
Group type: EXPERIMENTAL
Intervention: AWRK6 synthetic peptide via intraperitoneal injection
Number of subjects: 0
Study 34118361 — intervention group
Group type: EXPERIMENTAL
Intervention: AWRK6 synthetic peptide in oleic acid-induced HepG2 fatty liver cell model
Number of subjects: 0
Study 34118361 — intervention group
Group type: EXPERIMENTAL
Intervention: AWRK6 synthetic peptide in insulin-induced HepG2 cells
Number of subjects: 0
Study 34118396 — intervention group
Group type: EXPERIMENTAL
Intervention: mALPS-index
Number of subjects: 330
Study 34118856 — intervention group
Group type: EXPERIMENTAL
Intervention: Care of the Dying Evaluation - Emergency Medicine questionnaire
Number of subjects: 30
Study 34118909 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents
Number of subjects: 476
Study 34118909 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adults
Number of subjects: 476
Study 34118909 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals who studied
Number of subjects: 476
Study 34118909 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents and young adults
Number of subjects: 476
Study 34118944 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (750 mg)
Number of subjects: 14
Study 34118944 — intervention group
Group type: COMPARATOR
Intervention: Control (no chloroquine)
Number of subjects: 14
Study 34118981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen group (PG)
Number of subjects: 121
Study 34118981 — intervention group
Group type: COMPARATOR
Intervention: Syringe group (SG)
Number of subjects: 121
Study 34118981 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 121
Study 34118986 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (LRGT)
Number of subjects: 0
Study 34118986 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34119038 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34120214 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous antigen-specific T-cells (Melan-A and MELOE-1) with subcutaneous IL-2
Number of subjects: 6